About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Embattled Drugmaker Valeant Pharmaceuticals Cuts Ties to Philidor RX

by Dr. Trupti Shirole on October 31, 2015 at 4:44 PM
Font : A-A+

 Embattled Drugmaker Valeant Pharmaceuticals Cuts Ties to Philidor RX

Valeant Pharmaceuticals informed that it was cutting ties with mail-order pharmacy Philidor RX, which will shut down operations as soon as possible. A key investor in the embattled drug company meanwhile said, "Valeant would survive despite a widening scandal over its relations with Philidor and its accounting practices."

Valeant had nurtured Philidor in its infancy when it sold only two Valeant acne drugs by mail order. The two signed a deal in 2014 that effectively gave Valeant limited control over Philidor as a distribution channel for its drugs, and an option to buy the pharmacy. The partnership saw Philidor aggressively market Valeant's more expensive drugs over cheaper generics preferred by insurers. This caught the attention of US lawmakers and investigators now looking into its pricing.

Advertisement

The scandal has sent Valeant's share price tumbling 60% in three months. J. Michael Pearson, chairman and chief executive of the Canadian drugmaker said, "We have lost confidence in Philidor's ability to continue to operate in a manner that is acceptable to Valeant and the patients and doctors we serve. The newest allegations about activities at Philidor raise additional questions about the company's business practices."

The announcement came after Citron Research, an influential short-seller, accused Valeant of creating a network of mail-order pharmacies to 'stuff the channel', a deceptive business practice involving inflating sales figures by sending retailers in its distribution channel more products than they are able to sell. It said, "Valeant was using two firms it purportedly controlled - Philidor and R&O Pharmacy. The latter is also embroiled in litigation with Valeant over non-payments for drug shipments. R&O insists it owes no arrears."
Advertisement

Valeant has refuted the accusations and asked the US Securities and Exchange Commission to investigate Citron. In a bid to boost the company's image, former US deputy attorney general Mark Filip was hired to advise Valeant's board. In a conference call Friday, October 30, 2015, Bill Ackman, the influential Wall Street activist investor whose Pershing Capital owns about 6% of Valeant, said, "The drug maker had done a poor job of countering attacks and explaining its operations and accounting. It would survive these recent setbacks. Life will go on for Valeant. While this has been a very damaging reputational moment we think that Valeant's business is very robust. We expect more negative press. In the meantime, we expect the business to perform well."

Pershing Square doubled down last week on its investment in the company, even as the shares kept tumbling. Despite Ackman's comments and the cutoff of Philidor, Valeant shares sank more than 10% on Friday to 99.34, a two-year low.

The Wall Street Journal reported that at Sequoia Fund, Valeant's largest institutional shareholder, two board members quit their positions earlier this week saying Sequoia held too large a position in the pharmaceutical firm. In a letter to shareholders on Thursday, October 29, 2015, Sequoia Fund criticized Valeant's handling of the situation and said, "We had caused an extraordinary level of (investor) pain, but are sticking by its investment. In our view, Valeant is an aggressively-managed business that may push boundaries, but operates within the law. We would stress the importance of taking a more systemic approach to managing business practices with an eye on the company's long-term corporate reputation."

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Get Involved and Stand Up for Human Rights on Human Rights Day 2022
Coronary Artery Bypass Grafting
Macronutrients Calculator for Weight Loss
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Look Taller 

Most Popular on Medindia

How to Reduce School Bag Weight - Simple Tips Nutam (400mg) (Piracetam) Blood - Sugar Chart Vent Forte (Theophylline) Blood Pressure Calculator Selfie Addiction Calculator Accident and Trauma Care Loram (2 mg) (Lorazepam) Color Blindness Calculator The Essence of Yoga
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Embattled Drugmaker Valeant Pharmaceuticals Cuts Ties to Philidor RX Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests